Viking Therapeutics Inc
VKTX
Company Profile
Business description
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Contact
9920 Pacific Heights Boulevard
Suite 350
San DiegoCA92121
USAT: +1 858 704-4660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
53
Stocks News & Analysis
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
stocks
ASX retail share remains cheap despite weaker earnings
Weaker profit result drives cut to fair value yet shares remain undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,712.80 | 44.30 | 0.51% |
| CAC 40 | 7,769.31 | 77.24 | -0.98% |
| DAX 40 | 22,612.97 | 344.11 | -1.50% |
| Dow JONES (US) | 45,960.11 | 469.38 | -1.01% |
| FTSE 100 | 9,972.17 | 134.67 | -1.33% |
| HKSE | 24,987.98 | 131.55 | 0.53% |
| NASDAQ | 21,408.08 | 521.74 | -2.38% |
| Nikkei 225 | 53,409.76 | 193.89 | -0.36% |
| NZX 50 Index | 12,935.39 | 6.09 | 0.05% |
| S&P 500 | 6,477.16 | 114.74 | -1.74% |
| S&P/ASX 200 | 8,516.30 | 44.70 | 0.53% |
| SSE Composite Index | 3,910.49 | 21.41 | 0.55% |